A Phase 1b/2a Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, Dose-Escalation Study With an Open-Label Part to Examine the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of TAK-935 as an Adjunctive Therapy in Subjects With Developmental and/or Epileptic Encephalopathies
Phase of Trial: Phase I/II
Latest Information Update: 04 Jan 2019
At a glance
- Drugs TAK 935 (Primary)
- Indications Dravet syndrome; Encephalopathy; Epilepsy; Lennox-Gastaut syndrome; Tuberous sclerosis
- Focus Adverse reactions
- Sponsors Takeda
- 04 Jan 2019 According to an Ovid Therapeutics media release, the company plans to submit this trial results for peer-review presentation at a scientific medical meeting in first half 2019.
- 17 Dec 2018 Results presented in an Ovid Therapeutics media release.
- 02 Nov 2018 Status changed from active, no longer recruiting to completed.
Most Recent Events
Table of Contents
- At a glance
- Trial Overview
- Trial Details
- Trial Centres
- Trial History